Fibroblast Growth Factor Receptor 3 Interacts with and Activates TGFbeta-Activated Kinase 1 Tyrosine Phosphorylation and NFkappaB Signaling in Multiple Myeloma and Bladder Cancer

Warning

This publication doesn't include Faculty of Medicine. It includes Faculty of Science. Official publication website can be found on muni.cz.

Authors	SALAZAR Lisa KASHIWADA Tamar KREJČÍ Pavel MEYER April CASALE Malcolm HALLOWELL Matthew WILCOX William DONOGHUE Daniel MICHELS THOMPSON Leslie
Year of publication	2014
Type	Article in Periodical
Magazine / Source	PLOS One
MU Faculty or unit	Faculty of Science
Citation
Web	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3900522/
Doi	http://dx.doi.org/10.1371/journal.pone.0086470
Field	Physiology
Keywords	FGFR3; TAK1; NFkappaB; multiple myeloma; bladder cancer
Description	Cancer is a major public health problem worldwide. In the United States alone, 1 in 4 deaths is due to cancer and for 2013 a total of 1,660,290 new cancer cases and 580,350 cancer-related deaths are projected. Comprehensive profiling of multiple cancer genomes has revealed a highly complex genetic landscape in which a large number of altered genes, varying from tumor to tumor, impact core biological pathways and processes. This has implications for therapeutic targeting of signaling networks in the development of treatments for specific cancers. The NFkappaB transcription factor is constitutively active in a number of hematologic and solid tumors, and many signaling pathways implicated in cancer are likely connected to NFkappaB activation. A critical mediator of NFkappaB activity is TGFbeta-activated kinase 1 (TAK1). Here, we identify TAK1 as a novel interacting protein and target of fibroblast growth factor receptor 3 (FGFR3) tyrosine kinase activity. We further demonstrate that activating mutations in FGFR3 associated with both multiple myeloma and bladder cancer can modulate expression of genes that regulate NFkappaB signaling, and promote both NFkappaB transcriptional activity and cell adhesion in a manner dependent on TAK1 expression in both cancer cell types. Our findings suggest TAK1 as a potential therapeutic target for FGFR3-associated cancers, and other malignancies in which TAK1 contributes to constitutive NFkappaB activation.
Related projects:	Molekulární základy FGFR3 signalingu v kostní dysplázii FGFR3-specifický adaptérom a jeho role v patologické FGFR3 signalizaci v nemoci